

TABLE 6.—MODELED PERCENTAGE DISTRIBUTION OF FOOD SERVINGS CONTAMINATED WITH *L. monocytogenes* AT TIME OF CONSUMPTION FOR FOODS THAT DO NOT SUPPORT GROWTH

Food Category	Median Percentage of Food Servings Contaminated with <i>L. monocytogenes</i> at:						
	1 cfu/serving (0.01 cfu/g) <sup>a</sup>	> 1 - 10 cfu/serving <sup>b</sup> (> 0.01-0.1 cfu/g)	> 10 - 100 cfu/serving <sup>c</sup> (> 0.1 - 1 cfu/g)	100 to 10 <sup>3</sup> cfu/serving <sup>d</sup> (> 1 - 10 cfu/g)	> 10 <sup>3</sup> - 10 <sup>4</sup> cfu/serving <sup>e</sup> (> 10 - 100 cfu/g)	> 10 <sup>4</sup> - 10 <sup>5</sup> cfu/serving <sup>f</sup> (> 100 - 1,000 cfu/g)	> 10 <sup>5</sup> - 10 <sup>6</sup> cfu/serving <sup>g</sup> (> 10 <sup>3</sup> - 10 <sup>4</sup> cfu/g)
<b>Seafood</b>							
Preserved Fish	0.9 (<0.1, 3.1) <sup>h</sup>	2.1 (0.1, 8.0)	1.2 (<0.1, 5.8)	0.6 (<0.1, 4.0)	0.2 (<0.1, 2.3)	0.1 (<0.1, 1.2)	0.1 (<0.1, <0.7)
<b>Dairy</b>							
Hard Cheese	<0.1 (<0.1, .5)	<0.1 (<0.1, 0.6)	<0.1 (<0.1, 0.4)	<0.1 (<0.1, 0.2)	<0.1 (<0.1, 0.1)	<0.1 (<0.1, <0.1)	<0.1 (<0.1, <0.1)
Processed Cheese	0.2 (<0.1, 0.6)	0.3 (<0.1, 0.9)	0.1 (<0.1, 0.4)	0.1 (<0.1, 0.2)	<0.1 (<0.1, 0.1)	<0.1 (<0.1, 0.1)	<0.1 (<0.1, <0.1)
Ice Cream/Frozen Dairy	0.1 (<0.1, 0.2)	0.2 (0.1, 0.3)	0.1 (<0.1, 0.1)	<0.1 (<0.1, <0.1)	<0.1 (<0.1, <0.1)	<0.1 (<0.1, <0.1)	<0.1 (<0.1, <0.1)
Cultured Milk Products	0.1 (<0.1, 1.1)	0.2 (<0.1, 1.5)	0.1 (<0.1, 0.8)	<0.1 (<0.1, 0.4)	<0.1 (<0.1, 0.2)	<0.1 (<0.1, 0.1)	<0.1 (<0.1, <0.1)
Deli-type salads	1.9 (0.7, 3.7)	3.0 (0.9, 5.2)	1.1 (0.3, 1.9)	0.3 (0.1, 0.7)	0.1 (<0.1, 0.2)	<0.1 (<0.1, 0.1)	<0.1 (<0.1, <0.1)

<sup>a</sup> Assumes a uniform serving size of 100 g.<sup>b</sup> Includes combined estimates for doses of 3.16 and 10 cfu.<sup>c</sup> Includes combined estimates for doses of 31.6 and 100 cfu.<sup>d</sup> Includes combined estimates for doses of 316 and 1,000 cfu.<sup>e</sup> Includes combined estimates for doses of 3160 and 10,000 cfu.<sup>f</sup> Includes combined estimates for doses of 31,600 and 100,000 cfu.<sup>g</sup> Includes combined estimates for doses of 316,000 and 1,000,000 cfu.<sup>h</sup> Numbers in parentheses denote the 5th and 95th percentile uncertainty levels, respectively.

Dated: January 23, 2008.

**Margaret O'K. Glavin,**

Associate Commissioner for Regulatory Affairs.

[FR Doc. 08-549 Filed 2-6-08; 8:45 am]

BILLING CODE 4160-01-S

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration****Radiological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of Committee:* Radiological Devices Panel of the Medical Devices Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on March 4, 2008, from 8 a.m. to 5:30 p.m., and March 5, 2008, from 8 a.m. to 5 p.m.

*Location:* Hilton Washington DC North/Gaithersburg, Salons A, B, and C, 620 Perry Pkwy., Gaithersburg, MD.

*Contact Person:* Nancy Wersto, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 240-276-3666, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512526. Please call the Information Line for up-to-date information on this meeting. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency's Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

*Agenda:* On March 4 and 5, 2008, the committee intends to discuss and make recommendations about computer aided detection and diagnosis (CAD) devices

for radiological images, e.g., mammograms, chest x-rays, and computed tomography (CT) images of the lungs or colon. There will be a general discussion focusing on the general methodologies for CAD, including how CAD devices are used in clinical decision-making, how the devices are tested, and the information needed to properly assess their safety and effectiveness. The general discussion will be followed by specific discussions related to mammography CAD devices, colon CAD devices, and lung CAD devices. These discussions will include how the different types of CAD devices are used and the literature published regarding these devices, with focus on testing issues related to the different devices.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <http://www.fda.gov/ohrms/>

[dockets/ac/acmenu.htm](http://dockets/ac/acmenu.htm), click on the year 2008 and scroll down to the appropriate advisory committee link.

**Procedure:** On March 4, 2008, from 8 a.m. to 5:30 p.m., and on March 5, 2008, from 8:30 a.m. to 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before February 19, 2008. Oral presentations from the public will be scheduled between approximately 10 a.m. and 10:30 a.m., and between 3:15 p.m. and 3:45 p.m. on March 4, 2008, and between approximately 9:10 a.m. and 9:40 a.m., and between 2:15 p.m. and 2:45 p.m. on March 5, 2008. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before February 11, 2008. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by February 12, 2008.

**Closed Presentation of Data:** On March 5, 2008, from 8 a.m. to 8:30 a.m., the meeting will be closed so that the committee may receive an update from FDA about devices under evaluation that may be brought before the committee in the near future. This portion of the meeting will be closed because it involves the discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)).

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Shirley Meeks, Conference Management Staff, at 240-276-8931, at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at <http://www.fda.gov/oc/advisory/>

[default.htm](http://default.htm) for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 28, 2008.

**Randall W. Lutter,**

*Deputy Commissioner for Policy.*

[FR Doc. E8-2265 Filed 2-6-08; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Human Genome Research Institute Special Emphasis Panel, T32 Application.

**Date:** March 6, 2008.

**Time:** 12 p.m. to 1 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892. (Telephone Conference Call)

**Contact Person:** Rudy O. Pozzatti, PhD, Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, MSC 9306, Rockville, MD 20852, (301) 402-0838, [pozatttr@mail.nih.gov](mailto:pozatttr@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

January 31, 2008.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 08-520 Filed 2-6-08; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Neurological Disorders and Stroke Initial Review Group, Neurological Sciences and Disorders B.

**Date:** February 28-29, 2008.

**Time:** 8 a.m. to 6 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Admiral Fell Inn, Historic Fell's Point, 888 South Broadway, Baltimore, MD 21231.

**Contact Person:** W. Ernest Lyons, PhD, Scientific Review Officer, Scientific Review Branch NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892-9529, 301-496-4056.

**Name of Committee:** National Institute of Neurological Disorders and Stroke Initial Review Group, Neurological Science and Disorders K.

**Date:** March 3-4, 2008.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037.

**Contact Person:** Shanta Rajaram, PhD, Scientific Review Officer, Division of Extramural Research, NIH/NIND/RSB, Neuroscience Center, 6601 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20852, (301) 435-6033, [rajarams@mail.nih.gov](mailto:rajarams@mail.nih.gov).

**Name of Committee:** National Institute of Neurological Disorders and Stroke Initial Review Group, Neurological Sciences and Disorders A.

**Date:** March 5-6, 2008.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** The Portofino Hotel, 260 Portofino Way, Redondo Beach, CA 90277.

**Contact Person:** Richard D. Crosland, PhD, Scientific Review Officer, Scientific Review Branch, Division of Extramural Research,